Skip to main content

Advertisement

Log in

Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats

  • Original Paper
  • Published:
Journal of Physiology and Biochemistry Aims and scope Submit manuscript

Abstract

The possible effectiveness of resveratrol, a polyphenol present in different plants comprising berries, grapes and peanuts, on the prevention of doxorubicin-induced cardiac toxicity and fibrosis was investigated. Forty adult male Wistar albino rats were divided into four groups. Group I received normal saline, group II gavaged with resveratrol (20 mg/kg, daily for 4 weeks), group III received doxorubicin (2.5 mg/kg i.p. in six injections for 2 weeks; accumulative dose of 15 mg/kg), and group IV received doxorubicin + resveratrol (starting resveratrol intake 2 weeks before doxorubicin administration). Resveratrol significantly alleviated the increase in left ventricular lipid peroxidation, hydroxyproline, and tumor necrosis factor alpha levels as well as serum creatine kinase-myocardial band (CK-MB) activity and prevented the decrease in body and heart weights in doxorubicin-treated group. However, a marked protection against reduced glutathione content depletion and superoxide dismutase activity reduction was observed in the left ventricles of rats pretreated with resveratrol in combination with doxorubicin. Resveratrol also ameliorated the up-regulation of left ventricular caspase-3 and transforming growth factor-beta1 gene expression as well as left ventricular histopathological changes including necrosis and fibrosis induced by doxorubicin. Collectively, our results suggest that resveratrol provides a significant protection against doxorubicin-induced cardiotoxicity and fibrosis in rats. Therefore, it may be used as a promising cardioprotective agent in patients treated with doxorubicin due to malignant diseases. So, further clinical trials are required to confirm these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24:2783–2840

    PubMed  CAS  Google Scholar 

  2. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, El-Eraky WI, El-Shemy HA (2011) Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 44(6):591–601

    Article  PubMed  CAS  Google Scholar 

  3. Arunachalam S, Kim SY, Lee SH, Lee YH, Kim MS, Yun BS, Yi HK, Hwang PH (2012) Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo. J Nat Med 66:149–157

    Article  PubMed  CAS  Google Scholar 

  4. Beutler E, Duron O, Kelly BM (1963) Improved method for the determination of blood glutathione. J Lab Clin Med 61:882–888

    PubMed  CAS  Google Scholar 

  5. Cao Z, Li Y (2004) Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 489(1–2):39–48

    Article  PubMed  CAS  Google Scholar 

  6. Chan V, Fenning A, Iyer A, Hoey A, Brown L (2011) Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 12:429–436

    Article  PubMed  CAS  Google Scholar 

  7. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS (2004) Resveratrol-associated renal toxicity. Toxicol Sci 82(2):614–619

    Article  PubMed  CAS  Google Scholar 

  8. Danz ED, Skramsted J, Henry N, Bennett JA, Keller RS (2009) Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 46:1589–1597

    Article  PubMed  Google Scholar 

  9. Dernek S, Ikizler M, Erkasap N, Ergun B, Koken T, Yilmaz K, Sevin B, Kaygisiz Z, Kural T (2004) Cardioprotection with resveratrol pretreatment: improved beneficial effects over standard treatment in rat hearts after global ischemia. Scand Cardiovasc J 38(4):245–254

    Article  PubMed  CAS  Google Scholar 

  10. Díaz-Chávez J, Fonseca-Sánchez MA, Arechaga-Ocampo E, Flores-Pérez A, Palacios-Rodríguez Y, Domínguez-Gómez G, Marchat LA, Fuentes-Mera L, Mendoza-Hernández G, Gariglio P, López-Camarillo C (2013) Proteomic profiling reveals that resveratrol inhibits hsp27 expression and sensitizes breast cancer cells to doxorubicin therapy. PLoS One 8(5):e64378

    Article  PubMed  PubMed Central  Google Scholar 

  11. Dudka J, Gieroba R, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, Mandziuk S, Korobowicz E, Murias M (2012) Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Evid Based Complement Alternat Med 2012:606183

    Article  PubMed  PubMed Central  Google Scholar 

  12. Elberry AA, Abdel-Naim AB, Abdel-Sattar EA, Nagy AA, Mosli HA, Mohamadin AM, Ashour OM (2010) Cranberry (Vaccinium macrocarpon) protects against doxorubicin-induced cardiotoxicity in rats. Food Chem Toxicol 48:1178–1184

    Article  PubMed  CAS  Google Scholar 

  13. El Boghdady NA (2013) Antioxidant and antiapoptotic effects of proanthocyanidin and ginkgo biloba extract against doxorubicin-induced cardiac injury in rats. Cell Biochem Funct 31:344–351

    Article  PubMed  Google Scholar 

  14. Fujita M, Shannan JM, Morikawa O, Gauldie J, Hara N, Masan RJ (2003) Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Am J Respir Cell Mol Biol 29:1–7

    Article  Google Scholar 

  15. Gu J, Song ZP, Gui DM, Hu W, Chen YG, Zhang DD (2012) Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc Toxicol 12(4):341–349

    Article  PubMed  CAS  Google Scholar 

  16. Guo R, Lin J, Xu W, Shen N, Mo L, Zhang C, Feng J (2013) Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells. Int J Mol Med 31:644–650

    PubMed  CAS  Google Scholar 

  17. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB (2011) Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 1215:150–160

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Han X, Ren D, Fan P, Shen T, Lou H (2008) Protective effects of naringenin-7-O-glucoside on doxorubicin-induced apoptosis in H9C2 cells. Eur J Pharmacol 581:47–53

    Article  PubMed  CAS  Google Scholar 

  19. Holly TA, Drincic A, Byun Y, Nakamura S, Harris K, Klocke FJ, Cryns VL (1999) Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol 31(9):1709–1715

    Article  PubMed  CAS  Google Scholar 

  20. Juan ME, Vinardell MP, Planas JM (2002) The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132(2):257–260

    PubMed  CAS  Google Scholar 

  21. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El May M, Gharbi N, Kamoun A, El-Fazaâ S (2007) Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci 80(11):1033–1039

    Article  PubMed  CAS  Google Scholar 

  22. Kavas GO, Ayral PA, Elhan AH (2013) The effects of resveratrol on oxidant/antioxidant systems and their cofactors in rats. Adv Clin Exp Med 22(2):151–155

    PubMed  Google Scholar 

  23. Kliment CR, Suliman HB, Tobolewski JM, Reynolds CM, Day BJ, Zhu X, McTiernan CF, McGaffin KR, Piantadosi CA, Oury TD (2009) Extracellular superoxide dismutase regulates cardiac function and fibrosis. J Mol Cell Cardiol 47:730–742

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Koti BC, Vishwanathswamy AH, Wagawade J, Thippeswamy AH (2009) Cardioprotective effect of lipistat against doxorubicin induced myocardial toxicity in albino rats. Indian J Exp Biol 47:41–46

    PubMed  CAS  Google Scholar 

  25. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T (2002) Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106(1):130–135

    Article  PubMed  CAS  Google Scholar 

  26. Li Y, Liu Y, Fu Y, Wei T, Le Guyader L, Gao G, Liu RS, Chang YZ, Chen C (2012) The triggering of apoptosis in macrophages by pristine graphene through the MAPK and TGF-beta signaling pathways. Biomaterials 33:402–411

    Article  PubMed  Google Scholar 

  27. Lowry OH, Rosebrough N, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275

    PubMed  CAS  Google Scholar 

  28. Migrino RQ, Aggarwal D, Konorev E, Brahmbhatt T, Bright M, Kalyanaraman B (2008) Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol 34:208–214

    Article  PubMed  PubMed Central  Google Scholar 

  29. Mohamed HE, Asker ME, Ali SI, El-Fattah TM (2004) Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. J Pharm Pharmacol 56:757–768

    Article  PubMed  CAS  Google Scholar 

  30. Nishikimi M, Roa NA, Yogi K (1972) The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem Bioph Res Common 46:849–854

    Article  CAS  Google Scholar 

  31. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–1225

    Article  PubMed  CAS  Google Scholar 

  32. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358

    Article  PubMed  CAS  Google Scholar 

  33. Oktem G, Uysal A, Oral O, Sezer ED, Olukman M, Erol A, Akgur SA, Bilir A (2012) Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp Toxicol Pathol 64(5):471–479

    Article  PubMed  CAS  Google Scholar 

  34. Osman AM, Al-Harthi SE, Alarabi OM, Elshal MF, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA, Osman OH (2013) Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int 13(1):52

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  35. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215:161–169

    Article  PubMed  CAS  Google Scholar 

  36. Rezk YA, Balulad SS, Keller RS, Bennett JA (2006) Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194:23–26

    Article  Google Scholar 

  37. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, Martines G, De Caterina R, Carluccio MA (2012) Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys 527:81–89

    Article  PubMed  CAS  Google Scholar 

  38. Shen M, Wu RX, Zhao L, Li J, Guo HT, Fan R, Cui Y, Wang YM, Yue SQ, Pei JM (2012) Resveratrol attenuates ischemia/reperfusion injury in neonatal cardiomyocytes and its underlying mechanism. PLoS One 7(12):e51223

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  39. Shuai YI, Guo IB, Peng S-G, Li-Shi Z, Guo J, Han G, Shen Dong Y (2007) Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. Toxicol Lett 170:66–74

    Article  PubMed  CAS  Google Scholar 

  40. Smoliga JM, Baur JA, Hausenblas HA (2011) Resveratrol and health—a comprehensive review of human clinical trials. Mol Nutr Food Res 55:1129–1141

    Article  PubMed  CAS  Google Scholar 

  41. Sõti C, Nagy E, Giricz Z, Vígh L, Csermely P, Ferdinandy P (2005) Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 146(6):769–780

    Article  PubMed  PubMed Central  Google Scholar 

  42. Tatlidede E, Sehirli O, Velioğlu-Oğünc A, Cetinel S, Yeğen BC, Yarat A, Süleymanoğlu S, Sener G (2009) Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 43(3):195–205

    Article  PubMed  CAS  Google Scholar 

  43. Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, Miyauchi T, Yamaguchi I (2006) Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 101:151–158

    Article  PubMed  CAS  Google Scholar 

  44. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo R, Csiszar A (2010) Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 299:H18–H24

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  45. Usta E, Mustafi M, Walker T, Ziemer G (2011) Resveratrol suppresses apoptosis in intact human cardiac tissue—in vitro model simulating extracorporeal circulation. J Cardiovasc Surg (Torino) 52:399–409

    CAS  Google Scholar 

  46. Vitaglione P, Ottanelli B, Milani S, Morisco F, Caporaso N, Fogliano V (2009) Dietary trans-resveratrol bioavailability and effect on CCl4-induced liver lipid peroxidation. J Gastroenterol Hepatol 24(4):618–622

    Article  PubMed  CAS  Google Scholar 

  47. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM (2002) Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 282:H1685–H1696

    PubMed  CAS  Google Scholar 

  48. Wang GY, Wang YM, Zhang LN, Li Q, Yue H, Song CM, Feng JK, Wang N (2007) Effect of resveratrol on heart function of rats with adriamycin-induced heart failure. Zhongguo Zhong Yao Za Zhi 32(15):1563–1565

    PubMed  CAS  Google Scholar 

  49. Xu X, Chen K, Kobayashi S, Timm D, Liang Q (2012) Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther 341(1):183–195

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  50. Yu W, Fu YC, Wang W (2012) Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 113:752–759

    Article  PubMed  CAS  Google Scholar 

  51. Zhang C, Lin G, Wan W, Li X, Zeng B, Yang B, Huang C (2012) Resveratrol, a polyphenol phytoalexin, protects cardiomyocytes against anoxia/reoxygenation injury via the TLR4/NF-κB signaling pathway. Int J Mol Med 29:557–563

    PubMed  CAS  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors are grateful to the laboratory animal technicians, Faculty of Medicine, Zagazig University, for their skillful and excellent work.

Conflict of interest

The authors declare that they have no conflicts of interest to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hebatallah Husseini Atteia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arafa, M.H., Mohammad, N.S., Atteia, H.H. et al. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem 70, 701–711 (2014). https://doi.org/10.1007/s13105-014-0339-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13105-014-0339-y

Keywords

Navigation